Condition: Solid Tumor, Adult · Sponsor: Grit Biotechnology
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
This description comes directly from the study's public registry record.
Zhengxiang Han, MD · +86 18052268612 · cnhzxyq@163.com
Always discuss trial participation with your own doctor first.
| Beijing Arion Cancer Center | Beijing, Beijing Municipality, China | Recruiting |
| Beijing GoBroad hospital | Beijing, Beijing Municipality, China | Recruiting |
| The Affiliated Hospital Of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06397963